Zinc α2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer

BJU International

Volumn 110, Issue 11 B, 2012, Pages

  Katafigiotis, Ioannis ^a   Tyritzis, Stavros I ^a   Stravodimos, Konstantinos G ^a   Alamanis, Christos ^a   Pavlakis, Kitty ^a   Vlahou, Antonia ^b   Makridakis, Manousos ^b   Katafigioti, Amalia ^a   Garbis, Spiros D ^c   Constantinides, Constantinos A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Biomarker; Prostate cancer; Zinc 2 glycoprotein

Indexed keywords

ALPHA2 GLYCOPROTEIN; BIOLOGICAL MARKER; DUTASTERIDE; FINASTERIDE; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; ZINC ALPHA2 GLYCOPROTEIN; SEMINAL PLASMA PROTEIN; TUMOR MARKER; ZN ALPHA 2 GLYCOPROTEIN; ZN-ALPHA-2-GLYCOPROTEIN;

AGED; AREA UNDER THE CURVE; ARTICLE; BODY FLUID; CANCER DIAGNOSIS; CANCER RISK; CANCER SURGERY; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; EARLY DIAGNOSIS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TRANSRECTAL ULTRASONOGRAPHY; WESTERN BLOTTING; DIFFERENTIAL DIAGNOSIS; ECHOGRAPHY; ENDOSCOPIC ULTRASOUND GUIDED FINE NEEDLE BIOPSY; MALE; METHODOLOGY; PATHOLOGY; PROSTATE; PROSTATE TUMOR; ULTRASTRUCTURE; URINALYSIS; URINE;

AGED; BLOTTING, WESTERN; DIAGNOSIS, DIFFERENTIAL; EARLY DIAGNOSIS; ENDOSCOPIC ULTRASOUND-GUIDED FINE NEEDLE ASPIRATION; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PROSTATE; PROSTATIC NEOPLASMS; ROC CURVE; SEMINAL PLASMA PROTEINS; TUMOR MARKERS, BIOLOGICAL; URINALYSIS;

MLCS; MLOWN;

EID: 84876449854     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11501.x     Document Type: Article

References (19)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29
2. Fitzpatrick JM, Schulman C, Zlotta AR, Schröder FH. Prostate cancer: a serious disease suitable for prevention. BJU Int 2009; 103: 864-70
3. Thompson IM, Ankerst DP, Chi C et al. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 2005; 294: 66-70
4. Tosoian J, Loeb S. PSA and beyond: the past, present, and future of investigative biomarkers for prostate cancer. Scientific World Journal 2010; 10: 1919-31
5. Guazzoni G, Nava L, Lazzeri M et al. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting. Eur Urol 2011; 60: 214-22
6. Hale LP, Price DT, Sanchez LM, Demark-Wahnefried W, Madden JF. Zinc alpha-2-glycoprotein is expressed by malignant prostatic epithelium and may serve as a potential serum marker for prostate cancer. Clin Cancer Res 2001; 7: 846-53
7. Garbis SD, Roumeliotis T et al. Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry. J Proteome Res 2008; 7: 3146-58
8. Henshall SM, Horvath LG, Quinn DI et al. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy. J Natl Cancer Inst 2006; 98: 1420-4
9. Schröder FH, Hugosson J, Roobol MJ et al. ERSPC investigators. Screening and prostate cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1351-4
10. Andriole GL, Grubb RL 3rd, Buys SS et al. PLCO Project Team. Mortality results from a randomized prostate cancer screening trial. N Engl J Med 2009; 360: 1310-9
11. Eckersberger E, Finkelstein J, Sadri H et al. Screening for prostate cancer: a review of the ERSPC and PLCO trials. Rev Urol 2009; 11: 127-33
12. Bondar OP, Barnidge DR, Klee EW, Davis BJ, Klee GG. LC-MS/MS quantification of Zn-alpha2 glycoprotein: a potential serum biomarker for prostate cancer. Clin Chem 2007; 53: 673-8
13. Hirai K, Hussey HJ, Barber MD, Price SA, Tisdale MJ. Biological evaluation of a lipid-mobilizing factor isolated from thEurine of cancer patients. Cancer Res 1998; 58: 2359-63
14. Byrne JC, Downes MR, O ' Donoghue N et al. 2D-DIGE as a strategy to identify serum markers for the progression of prostate cancer. J Proteome Res 2009; 8: 942-57
15. O ' Hurley G, O ' Grady A, Smyth P et al. Evaluation of zinc-alpha-2-glycoprotein and proteasome subunit beta-type 6 expression in prostate cancer using tissue microarray technology. Appl Immunohistochem Mol Morphol 2010; 18: 512-7
16. Descazeaud A, Taille A, Allory Y et al. Characterization of ZAG protein expression in prostate cancer using a semi-automated microscope system. Prostate 2006; 66: 1037-43
17. Sreekumar A, Poisson LM, Rajendiran TM et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009; 457: 799-800
18. Schostak M, Schwall GP, Poznanović S et al. Annexin A3 in urine: a highly specific non invasive marker for prostate cancer early detection. J Urol 2009; 181: 343-53
19. Hessels D, Smit FP, Verhaegh GW, Witjes JA, Cornel EB, Schalken JA. Detection of MPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer. Clin Cancer Res 2007; 13: 5103-8